Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cros NT has expanded into Europe through the creation of CROS DE, a new wholly-owned subsidiary based in Augsburg, Germany. The company born from Estimate, a Germany-based CRO, is specialized in providing statistical services to pharmaceuticals and biotechnology industries.
Subscribe to our email newsletter
Cros NT said that Estimate, which has expertise and a particular excellence concerning the oncology and dermatology-related research, would enrich it.
Estimate, found in 1992, is a privately held company led by Thomas Zwingers, who is managing director and now a medical scientific director of Cros DE. In He will play a leading role in the operations, strategic planning, and corporate development of Cros’ portfolio of pharmaceuticals and biotechnology business.
Paolo Morelli, managing director of Cros NT, said: “Mr Zwingers is an exceptional addition to our team. CROS NT is establishing its presence in Germany, his substantial clinical and scientific expertise will be beneficial in expanding into the German market.”
Cros NT is a CRO specializing in clinical data management, statistical analysis, eCRF, ePRO and Life Science Application Hosting services. It implements rapid execution applications of clinical study tasks.
Cros NT is reported to have been completed over 700 studies in a range of therapeutic areas like respiratory, oncology, cardiovascular, HIV and Infectious diseases of clinical and observational studies. The clients and partners are pharmaceuticals, biotechnology, medical device and academic organizations in Europe and US.